Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Vericel Corporation (VCEL)

Vericel Corporation (VCEL)
16.60 x 2 50.51 x 1
Post-market by (Cboe BZX)
41.23 +0.41 (+1.00%) 04/17/25 [NASDAQ]
16.60 x 2 50.51 x 1
Post-market 41.23 unch (unch) 16:35 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
40.56
Day High
41.59
Open 40.72
Previous Close 40.82 40.82
Volume 343,200 343,200
Avg Vol 541,710 541,710
Stochastic %K 44.11% 44.11%
Weighted Alpha -17.55 -17.55
5-Day Change -0.67 (-1.60%) -0.67 (-1.60%)
52-Week Range 37.76 - 63.00 37.76 - 63.00
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,067,107
  • Shares Outstanding, K 50,136
  • Annual Sales, $ 237,220 K
  • Annual Income, $ 10,360 K
  • EBIT $ 5 M
  • EBITDA $ 10 M
  • 60-Month Beta 1.61
  • Price/Sales 8.63
  • Price/Cash Flow 134.45
  • Price/Book 7.10

Options Overview Details

View History
  • Implied Volatility 76.14% ( +9.80%)
  • Historical Volatility 57.84%
  • IV Percentile 97%
  • IV Rank 64.72%
  • IV High 95.56% on 04/08/25
  • IV Low 40.50% on 05/20/24
  • Put/Call Vol Ratio 1.00
  • Today's Volume 4
  • Volume Avg (30-Day) 25
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 1,087
  • Open Int (30-Day) 1,005

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.09
  • Number of Estimates 3
  • High Estimate -0.07
  • Low Estimate -0.10
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.76 +9.19%
on 04/08/25
Period Open: 47.60
48.74 -15.42%
on 03/25/25
-6.37 (-13.38%)
since 03/17/25
3-Month
37.76 +9.19%
on 04/08/25
Period Open: 59.07
63.00 -34.56%
on 02/05/25
-17.84 (-30.20%)
since 01/17/25
52-Week
37.76 +9.19%
on 04/08/25
Period Open: 46.26
63.00 -34.56%
on 02/05/25
-5.03 (-10.87%)
since 04/17/24

Most Recent Stories

More News
Vericel to Present at Multiple Upcoming Investor Conferences

VCEL : 41.23 (+1.00%)
Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results

VCEL : 41.23 (+1.00%)
Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025

VCEL : 41.23 (+1.00%)
Stocks Climb Before the Open on Fed Rate Cut Bets, U.S. Economic Data and Earnings on Tap

March S&P 500 E-Mini futures (ESH25) are up +0.31%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.49% this morning, signaling further gains on Wall Street as cooling U.S. core inflation bolstered...

CFR.Z.IX : 136.450 (+1.37%)
NFLX : 973.03 (+1.19%)
NVDA : 101.49 (-2.87%)
BAC : 37.41 (+0.21%)
PNC : 152.33 (+0.52%)
USB : 38.20 (+1.00%)
MS : 109.18 (+1.22%)
JBHT : 129.23 (+3.61%)
DDOG : 91.18 (-0.76%)
GS : 509.49 (+2.09%)
ESH25 : 5,617.80s (-0.79%)
UNH : 454.11 (-22.38%)
Stocks Surge as Core CPI Comes in Below Expectations

The S&P 500 is surging +1.34% this morning after the CPI and earnings reports from some of the biggest U.S. banks.

C : 63.25 (+1.85%)
$SPX : 5,282.70 (+0.13%)
JPM : 231.96 (+1.02%)
GS : 509.49 (+2.09%)
URI : 591.50 (+1.07%)
KBH : 51.67 (+3.03%)
S : 16.82 (-1.64%)
WFC : 64.71 (+1.14%)
MASS : 4.76 (+4.97%)
LLY : 839.96 (+14.30%)
ADBE : 348.80 (+1.34%)
SOFI : 10.98 (+3.00%)
Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets

VCEL : 41.23 (+1.00%)
Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

VCEL : 41.23 (+1.00%)
Vericel Reports Third Quarter 2024 Financial Results

VCEL : 41.23 (+1.00%)
Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024

VCEL : 41.23 (+1.00%)
Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor

/PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments...

ATRS : 5.59 (unch)
VCEL : 41.23 (+1.00%)
SGTX : 22.47 (-2.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the...

See More

Key Turning Points

3rd Resistance Point 42.72
2nd Resistance Point 42.16
1st Resistance Point 41.69
Last Price 41.23
1st Support Level 40.66
2nd Support Level 40.10
3rd Support Level 39.63

See More

52-Week High 63.00
Fibonacci 61.8% 53.36
Fibonacci 50% 50.38
Fibonacci 38.2% 47.40
Last Price 41.23
52-Week Low 37.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro